Business · Companies · 8 hrs ago

Sanofi considers buying US drugmaker Insmed

Sanofi considers buying US drugmaker Insmed

Sanofi is considering buying US drugmaker Insmed, but no deal has been agreed.

Bloomberg says Sanofi has hired advisers and talks could continue for weeks.

Insmed shares rose by as much as 24% on Thursday, valuing the company at about $30 billion, while Sanofi shares fell nearly 4%.

An offer could cost more than Insmed's current market value and be near the upper limit of what Sanofi can afford, according to an analyst.

Sanofi is seeking new medicines to offset potential revenue losses when the patent on Dupixent, its top-selling treatment for skin conditions and asthma, expires.

Sanofi sees acquisitions as a way to grow, but other buyers could make offers and the outcome remains uncertain.

1 source

Related

What people are saying

Michael LeutenJefferies analyst
The purchase price will probably be above the current market capitalization and would therefore be at the upper end of Sanofi’s financial capacity but by no means unattainable.
via Handelsblatt